Pfizer’s Experimental Weight Loss Drug Reveals Promise as a As soon as-a-Month Shot

The competitors to develop the subsequent blockbuster weight reduction drug is heating up, and Pfizer is trying to make an enormous splash with its personal entry.

On Tuesday, Pfizer presented the most recent trial knowledge on its ultra-long-acting GLP-1 experimental drug, code-named PF’3944. Folks taking PF’3944 misplaced considerably extra weight than these on a placebo, the trial confirmed, even after switching to a month-to-month schedule. The corporate will push ahead a number of Section III trials of the drug this 12 months.

A possible leg up

Pfizer acquired PF’3944 as a part of its bigger buyout of the biotech firm Metsera, completed final November.

Much like current medicines in the marketplace like semaglutide (Ozempic and Wegovy), PF’3944 mimics GLP-1, a hormone necessary to regulating our starvation and metabolism. But it surely’s designed to remain within the physique longer than present GLP-1s, ideally permitting for a much less cumbersome dosing schedule.

The Section 2b VESPER-3 examine examined how folks on PF’3944 would fare after shifting to a much less frequent dose. The volunteers have been overweight and obese people who didn’t have kind 2 diabetes. They have been randomized to obtain a weekly dose of the drug or placebo for the primary 12 weeks. From weeks 13 to twenty-eight, they transitioned into month-to-month upkeep photographs.

As with different GLP-1 medication, folks taking PF’3944 misplaced considerably extra weight than the placebo group. By week 28, customers had misplaced as much as 12.3% of their physique weight in comparison with placebo. There gave the impression to be no plateau within the price of individuals’s weight reduction by week 28, suggesting the month-to-month swap didn’t hamper the drug’s effectiveness and that its peak might nonetheless be increased. (For different GLP-1s, max weight reduction is often reached by 12 months one). PF’3944 additionally gave the impression to be usually well-tolerated, with the commonest hostile occasions being gastrointestinal, as is typical for this drug class.

“These topline outcomes from the Section 2b VESPER-3 examine reinforce the potential of PF’3944 as a month-to-month remedy with aggressive efficacy,” stated Jim Record, chief inner drugs officer at Pfizer, in a press release from the corporate.

What’s subsequent

The VESPER-3 examine continues to be ongoing and can proceed till members have been on the drug for 64 weeks. However given the promising outcomes so removed from this and different research, Pfizer is already shifting forward with additional improvement.

In 2026, the corporate will advance 10 Section 3 trials of PF’3944, which can try it out as each a weekly and month-to-month injection. Based mostly on earlier examine knowledge, the corporate has additionally determined to judge the security and effectiveness of a bigger month-to-month upkeep dose in a few of these trials.

Pfizer isn’t the one biotech attempting to realize a bonus available in the market by growing extra conveniently timed GLP-1 medication. Amgen’s MariTide—which mixes a GLP-1 agonist with a GIP antagonist—can also be being tested as a month-to-month injection, with a number of Section III trials within the works.